Genetic modification will dramatically increase ableism
Marsha Greene & Zubin Master, 2018, Senior Policy Analyst, Peraton & Biomedical Ethics Research Program, Mayo Clinic, https://www.ndu.edu/Portals/59/Documents/Incoming/AY21%20Briefings/NDU%206070/CRISPR_Military.pdf?ver=2020-08-11-170728-347, " Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement" Journal of Bioethical Inquiry (ermo/sms, Acc:6-8-2022)
CRISPR has revitalized the debate over human gene enhancement. In contemporary bioethics debates, a distinction between gene editing to treat or prevent disease and enhancement for non-health purposes is sometimes made with the latter being more strongly discouraged (Scheufele et al. 2017; Annas and Annas 2009; Ashcroft 2008; Amoroso and Wenger 2003). The distinction is meant to draw a line between practices that are considered morally permissible (gene editing for therapeutic purposes) versus those that are prohibitory (gene editing for enhancement) (Buchanan et al. 2000). Therapy is considered medically necessary in order to achieve normal function. But what is considered Bnormal^ function and what is Bpathological^ is susceptible to change. Yet in some cases, the moral difference between the therapy versus enhancement distinction becomes blurry. The classic example of two young boys both of whom are born with very short stature helps illustrate this point. Boy A is born short due to a deficiency in the human growth hormone (HGH) gene whereas Boy B is born short because both his parents are very short. Using CRISPR to correct the mutation in Boy A would be considered therapy because of a known gene defect whereas performing gene editing for Boy B would be considered enhancement because there is no clearly identifiable clinical pathology. Yet both Boy A and Boy B would suffer the social prejudice known as heightism, both desire to be taller, and both have very short statures due to a genetic lottery and to no fault of their own. In this situation, it would be ethically permissible to help both boys (Buchanan et al. 2000). Additionally, what may be considered an enhancement now might be considered treatment or routine care in the future (Frankel and Chapman 2000; Buchanan et al. 2000). In the above example, if we knew the specific set of genes making Boy B very short, this may be labelled as a pathology and thus could benefit from CRISPR therapy.
But there are valid reasons for maintaining the therapy/enhancement distinction including concerns that enhancement may be a form of a new, albeit softer, eugenics which likely furthers inequality among those who cannot afford to create children with enhanced traits (Frankel and Chapman 2000; Kiuru and Crystal 2008; Comfort 2015). The disability community finds the topic of gene modification particularly concerning. Many are concerned that the medical model characterizes disabilities as a medical problem that must be mitigated or eliminated (Generations Ahead 2010). Disability is a social construct with a socially dominant view that disabled people are unhappy and discounts the pride which people have in their disabilities and how it brings diverse and new perspectives to the world (Shakespeare 1995, 1998). Several in the disability community view genetic modification to rid disabilities in the world as highly discriminatory and argue that efforts towards such goals may increase social intolerance and further prejudice disabled persons.
There are, however, dissenting opinions as some argue enhancements are good for society and consider human enhancement a moral obligation (Savulescu 2005; Harris 2007). Based on the principle of procreative beneficence, Julian Savulescu argues that short of having competing interests, such as harm to a pregnant mother, parent(s) are obligated to have the most advantaged child, including by genetic enhancement (Savulescu 2001; Savulescu and Kahane 2009). Not all enhancements might be permissible, such as aesthetic ones like eye colour, but those that improve human flourishing, such as intelligence, would be allowed (Chan and Harris 2007).
For the purposes of our discussion here, we will not focus on the permissibility of enhancements in general or even for military purposes. Instead, we begin from the premise that CRISPR for military enhancement may be permitted and focus on outlining ethical issues surrounding risks and benefits to subjects, informed consent, and inequalities of access.